Pathologists at the Stanford University School of Medicine are trying out a new test from a Sunnyvale company that could give cancer patients a better chance of getting the most effective treatment.

UK-based AI and machine learning firm PinPoint has raised more than £1 million to develop a test designed to rule out cancer in the early stages and save millions for the NHS in unnecessary testing.

Life Technologies acquired Pinpoint Genomics and its early-stage non-small-cell lung cancer test. The test is designed to identify early-stage patients at high risk for progression to late-stage ...

An inexpensive, fast accurate DNA test that reveals a person's risk of developing certain diseases is expected to become a reality, thanks to new technology. An inexpensive, fast, accurate DNA test ...

A business behind AI-driven cancer diagnostic software which is designed to "enhance diagnostic accuracy and speed" has raised funds to expand its team and accelerate development. PinPoint's test has ...

Colon cancer is one of the top three deadliest forms of cancer - in part because it's often diagnosed so late. Now a groundbreaking study could pinpoint the disease easier, and earlier. The ...

CARLSBAD, Calif., July 25, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Pinpoint Genomics, Inc., and its early-stage non-small cell lung cancer ...